Abstract
BackgroundAdoptive cell therapy (ACT) with genetically-modified T cells has shown impressive results against some hematologic cancers, but limited efficacy against tumors with restrictive tumor microenvironments (TMEs). FasL is a particular...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have